Real‐World Efficacy of Extending Duration of Letermovir Prophylaxis for Allogeneic Stem Cell Recipients
Transplant Infectious Disease · 2025-11 · 27 (6)
DOI: 10.1111/tid.70116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, online erschienen am 14.10.2025. Verfasst von Yasutaka Masuda und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Antiviral Agents, Acetates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Cytomegalovirus (CMV) reactivation following allogeneic hematopoietic stem cell transplantation (HSCT) leads to significant morbidity and mortality. Recently, a pivotal trial demonstrated extended duration of letermovir until post‐HSCT Day 200 reduced clinically significant CMV infection (csCMVi). Here we evaluated the real‐world efficacy of extended letermovir.
Methods
We retrospectively reviewed consecutive patients who underwent HSCT and received letermovir prophylaxis for CMV seropositivity of the donor and/or the recipient at a transplant center between July 2018 and March 2024.
Results
A total of 236 HSCTs with letermovir prophylaxis were performed. Letermovir was administered until Days 75–125 in 189 cases, and until Day 150‐ in 37 cases, who were assigned as short and extended letermovir group, respectively. The cumulative incidence of csCMVi at Day 200 was significantly lower in cases with extended letermovir, with no patient developed csCMVi in this group compared to 26.8% in short prophylaxis group ( p < 0.001). However, the incidence was comparable at Day 400, with 19.7% in extended and 28.4% in short prophylaxis group ( p = 0.14). Multivariable analysis for csCMVi showed age ≥ 50 years at HSCT (hazard ratio [HR], 3.24; p < 0.001) and steroid administration at letermovir discontinuation (HR, 2.25; p = 0.003) were identified as significant risk factors, and patients with both factors were associated with higher incidence of csCMVi regardless of letermovir duration. Immunoglobulin G, but not lymphocyte count, was persistently lower in these high‐risk patients until Day 400.
Conclusion
Despite the efficacy of letermovir in preventing csCMVi during immunosuppression, the occurrence of csCMVi following letermovir cessation was still a clinical concern. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
- Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
ORCID-Profile: Yasutaka Masuda, Takashi Toya
Zitieren
APA
Masuda, Y., Toya, T., Yamakawa, R., Kojo, K., Kato, K., Sadaga, Y., Kondo, K., Kato, C., Hatsusawa, H., Ouchi, F., Terasaki, Y., Shimabukuro, M., Jinguji, A., Shimizu, H., Najima, Y., & Doki, N. (2025). Real‐World Efficacy of Extending Duration of Letermovir Prophylaxis for Allogeneic Stem Cell Recipients. Transplant Infectious Disease, 27(6). https://doi.org/10.1111/tid.70116
Vancouver
Masuda Y, Toya T, Yamakawa R, Kojo K, Kato K, Sadaga Y, et al. Real‐World Efficacy of Extending Duration of Letermovir Prophylaxis for Allogeneic Stem Cell Recipients. Transplant Infectious Disease. 2025;27(6). doi:10.1111/tid.70116
BibTeX
@article{Masuda2025,
author = {Masuda, Yasutaka and Toya, Takashi and Yamakawa, Riki and Kojo, Kairi and Kato, Kana and Sadaga, Yasutaka and Kondo, Kaori and Kato, Chika and Hatsusawa, Hiroki and Ouchi, Fumihiko and Terasaki, Yukie and Shimabukuro, Masashi and Jinguji, Atsushi and Shimizu, Hiroaki and Najima, Yuho and Doki, Noriko},
title = {Real‐World Efficacy of Extending Duration of Letermovir Prophylaxis for Allogeneic Stem Cell Recipients},
journal = {Transplant Infectious Disease},
year = {2025},
volume = {27},
number = {6},
doi = {10.1111/tid.70116}
}
EUVIMED